Biocon signs partnership agreement with Juno Pharmaceuticals

06 Oct 2023 Evaluate

Biocon has signed partnership agreement with Juno Pharmaceuticals, a specialty pharmaceutical company in Canada, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity. Under the terms of this agreement, Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market.

Juno is one of the fastest growing pharmaceutical companies in Canada that specializes in high-value generic, complex, biosimilar and other medicines of scarcity, to advance the quality of healthcare in the region. They are the country’s largest Canadian owned manufacturers of injectable medications, with a focus on supplying critical hospital medicines, in addition to medicines sold at retail pharmacies. Juno's mission is to ensure that patients have access to cost-effective and efficacious treatments.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

316.15 -4.65 (-1.45%)
31-Oct-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1849.05
Dr. Reddys Lab 1274.25
Cipla 1553.20
Lupin 2184.00
Zydus Lifesciences 1001.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.